IMB Dx, Inc. (KOSDAQ:461030)
South Korea · Delayed Price · Currency is KRW 3,505.00
-105.00 (-2.91%)
Aug 12, 2026, 1:53 PM KST
IMB Dx Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 5,600 | 5,329 | 3,407 | 4,027 | 2,625 | 1,230 |
Revenue Growth | 59.65% | 56.40% | -15.40% | 53.42% | 113.34% | - |
Gross Profit Gross Profit Growth | 1,515 | 1,386 | 888.05 | 1,417 | 364.57 | 28.76 |
Operating Income Operating Income Growth | -9,115 | -8,664 | -10,612 | -7,769 | -8,668 | -5,278 |
Net Income Net Income Growth | -8,407 | -7,934 | -9,577 | -10,416 | -10,436 | -9,789 |
Earnings Per Share EPS Growth | -599.12 | -565.99 | -715.00 | -1316.00 | -9742.01 | -9259.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Genetic Analysis Services and Medical Research Services Genetic Analysis Services and Medical Research Services Growth | 2,391 | 2,998 | 1,904 | 1,048 |
Genome Analysis Software Product Genome Analysis Software Product Growth | 964.83 | 1,011 | 679.55 | 179.95 |
Genome Analysis Software Merchandise Genome Analysis Software Merchandise Growth | 51.13 | 18.21 | 41.37 | 2.72 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 19,616 | 20,672 | 28,555 | 4,360 | 11,368 | 19,322 |
Total Debt Total Debt Growth | 650.3 | 437.73 | 433.37 | 320.3 | 243.96 | 200.46 |
Net Cash (Debt) Net Cash Growth | 18,966 | 20,234 | 28,121 | 4,040 | 11,124 | 19,122 |
Net Cash Growth | -28.13% | -28.05% | 596.15% | -63.69% | -41.82% | - |
Net Cash Per Share Net Cash Per Share Growth | 1351.50 | 1443.49 | 2099.56 | 510.35 | 10384.09 | 18087.16 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -6,901 | -6,202 | -6,647 | -6,231 | -6,326 | -4,011 |
Capital Expenditures CapEx Growth | -1,359 | -1,356 | -875.17 | -462.68 | -1,712 | -1,010 |
Free Cash Flow Free Cash Flow Growth | -8,260 | -7,559 | -7,522 | -6,694 | -8,038 | -5,021 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 27.05% | 26.02% | 26.07% | 35.20% | 13.89% | 2.34% |
Operating Margin | -162.77% | -162.60% | -311.47% | -192.92% | -330.23% | -428.97% |
Pretax Margin | -150.13% | -148.89% | -281.09% | -258.67% | -397.62% | -795.60% |
Profit Margin | -150.13% | -148.89% | -281.09% | -258.67% | -397.62% | -795.60% |
FCF Margin | -147.49% | -141.85% | -220.79% | -166.23% | -306.23% | -408.10% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 9.04 | 26.02 | 43.82 | - | - | - |